This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

Clinical disease activity index (CDAI) was the numerical sum of 4 outcome parameters: tender and swollen joint count based on a 28-joint assessment, participant global assessment and physician global assessment assessed on 0 to 10 millimeter (mm) visual analogue scale (VAS) where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). Total score for CDAI ranged from 0 to 76 with higher score indicating greater disease activity. Participants who achieved LDA had CDAI score less than or equal to (\<=)10. Participants with moderate or high disease activity (CDAI greater than \[\>\]10) at baseline were analyzed for this outcome measure.

Time frame: 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants with moderate or high disease activity (CDAI\>10) at baseline.

CDAI was the numerical sum of 4 outcome parameters: tender and swollen joint count based on a 28-joint assessment, participant global assessment and physician global assessment assessed on 0 to 10 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). CDAI total score = 0 to 76, higher scores=greater affection due to disease activity. CDAI \<2.8 indicated disease remission, 2.8 to \<10 indicated low disease activity, 10 to \<22 indicated moderate disease activity, and \>=22 indicated high disease activity.

Time frame: Baseline, 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit.

HAQ: participant-reported questionnaire for the assessment of rheumatoid arthritis. It comprised of 20 questions in 8 categories of activities: dress/groom; arise; eat; grip; walk; hygiene; reach; and activities over past week. Each activity was assessed on a 4-point Likert scale from 0 to 3, where 0 = without difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranged from 0 to 3, where 0 = least difficulty and 3 = extreme difficulty, higher scores indicating worse functioning.

Time frame: Baseline, 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.

Participant fatigue was measured on a VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.

Time frame: Baseline, 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit.

Participant pain was measured on a VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst).

Time frame: Baseline, 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit.

CDAI was the numerical sum of 4 outcome parameters: tender and swollen joint count based on a 28-joint assessment, participant global assessment and physician global assessment assessed on 0 to 10 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). Total score for CDAI ranged from 0 to 76 with higher score indicating greater disease activity. Participants who achieved clinical remission had a CDAI score \<=2.8. Participants with low, moderate or high disease activity (CDAI\>2.8) at baseline were analyzed for this outcome measure.

Time frame: 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants with moderate or high disease activity (CDAI\>2.8) at baseline.

mACR20 response: \>= 20% improvement in tender and swollen joint count and 20% improvement in two of the following four criteria: 1) participant assessment of pain (scored from 0 mm to 100 mm, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function).

Time frame: 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants with complete information for calculation of mACR.

mACR50 response: \>= 50% improvement in tender and swollen joint count and 50% improvement in two of the following four criteria: 1) participant assessment of pain (scored from 0 mm to 100 mm, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function).

Time frame: 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants with complete information for calculation of mACR.

mACR70 response: \>= 70% improvement in tender and swollen joint count and 70% improvement in two of the following four criteria: 1) participant assessment of pain (scored from 0 mm to 100 mm, higher scores indicated worsening of pain); 2) participant global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 3) physician global assessment of disease activity (scored from 0 to 100, higher scores indicated worsening of condition); 4) self-assessed disability index of the mHAQ (scored from 0 to 3, higher scores indicated worsening of function).

Time frame: 6 Months (from the retrospective data collected from the CorEvitas RA registry)

Population: All eligible participants who had CDAI available at baseline and at 6-months follow-up visit and CDAI measured at the 6-month follow-up visit. Here Number of Participants Analyzed signifies number of participants with complete information for calculation of mACR.